secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-05-12T20:10:15+00:00
Accession:  0001193125-26-219420
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 2026 net loss $4.1M; cash runway extended; FDA agrees path for tab-cel BLA resubmission
--------------------------------------------------------------------------------

- Net loss $4.1M ($0.29 diluted EPS) vs net income $38.0M ($3.50 diluted) in Q1 2025.
- Revenue $0.5M (prior Q1: $98.1M) due to FY2025 one-time tab-cel manufacturing transfer revenue.
- Cash $8.4M at Mar 31; plus $4.8M ATM proceeds post-quarter; runway into mid-2027.
- FDA agreed single-arm ALLELE study with historical control could support tab-cel BLA resubmission; update expected Q3 2026.
- R&D expenses $0.2M (vs $27.4M), G&A $3.6M (vs $11.5M) reflecting cost reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/0001193125-26-219420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526219420/atra-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer